How VisionOne™ is changing the future of glaucoma diagnostics

In our last article, we explored the growing crisis in global eye care. With 2.2 billion people living with vision impairment, and nearly half of these cases preventable, the challenge is not just clinical but systemic. Traditional diagnostics haven’t kept up, testing is slow, uncomfortable, and often not accessible. These issues are especially prominent in the management of chronic eye diseases like glaucoma, where early detection and consistent monitoring are critical.

VisionOne™ was built to change that. Created by PeriVision in partnership with Switzerland’s largest eye clinic, the Inselspital, VisionOne™ is a VR-based visual field testing platform designed for speed, accessibility, and clinical precision. It brings together patented AI, portable user-friendly hardware, and intuitive software to reimagine how glaucoma is detected and monitored.

What is VisionOne™?

VisionOne™ is a portable visual field testing platform powered by virtual reality and artificial intelligence. It replaces the traditional visual field machine with a lightweight, comfortable headset that can be used anywhere in a clinic, at home, or in mobile care settings.

It’s a complete system built around the needs of both patients and clinicians.

VisionOne™ provides a compelling value proposition for eye doctors:

• Fast AI-driven perimetry 

• Real-time results with standard outputs for EMRs

• Built-in eye tracking

• A virtual test assistant speaking several languages

• A customizable lensholder for precision

VisionOne™ offers the following benefits to clinics: 

• Free up staff with virtual assistant in multiple languages

• Free up space, test anywhere - even out of your clinic

• Offer a comfortable, ergonomic patient-experience

• Test multiple patients at the same time

• Work with standard outputs for EMR

• Up to 70% faster VFT with SORS

• Test without an eye patch

How VisionOne™ supports clinicians in real-world settings

VisionOne™ isn’t just a device, it’s a new way of delivering care. Clinics across Europe and the US are already integrating it into routine workflows. VisionOne™ is registered in the US with the FDA, in the EU with the CE-mark, and in the UK with UK MHRA, ensuring it meets the highest international standards for safety and efficacy.

It’s already being used in hospitals and eye care centers in Europe, the US, and Latin America. Our cloud-based architecture and data export tools allow easy integration into clinical workflows, enabling physicians detect changes, analyze trends and tailor interventions early.

Specialists rely on VisionOne’s™ test-retest consistency and data export tools to track progression and adjust treatment plans.

In our initial clinical studies :

• 95% of patients perceived the system as easy to use

• Technician time for visual field reduced by 63% with VR assistant

Clinicians reported in our market survey that they expect an average additional patient volume of 30% and that Visionone’s speed and automation frees up staff, reduces patient fatigue, and improves compliance.

What patients experience

Traditional perimetry often takes over 15 minutes per eye, is tiring, and can trigger anxiety. VisionOne™ changes that.

In a recent usability study, the average test duration was reduced to approximately 3 minutes per eye, significantly improving efficiency without compromising diagnostic quality.

Traditional VFT	VisionOne™
5–10 minutes per eye	~3 minutes per eye
Requires dark room & technician	Can be done anywhere
Uncomfortable, tiring	Comfort score: 8.75/10*
Stationary, expensive	Portable, scalable

*Source:  Acceptance, Tolerability and Patient Comfort during Home Based Visual Field Testing using a Virtual Reality Headset by  A. Lallouette et al. (2023)  - link 

SORS: a new standard in VFT

SORS (Sequentially Optimized Reconstruction Strategy) is a novel, AI-based visual field (VFT) strategy developed by the University of Bern and the Inselspital / University Hospital Bern, Switzerland’s largest eye clinic. SORS learned an optimal path to test a glaucomatous eye based on a training data set of thousands of visual field tests. It uses the learned correlations between the retinotopic test locations to reconstruct untested locations with high accuracy. This in turn allows strong reductions in test time.

Top left shows the starting visual field with age-normalized values. Bottom right shows the true visual field to be estimated. In between, the sequentially estimated visual fields using S 2 {5, 10, 15, 20, 25, 30} location measurements. Red points show the corresponding S tested locations.

Strong correlation with gold standard

SORS achieved strong correlations with Dynamic Strategy (DS), a gold standard in clinical practice. For instance, the model with 36 tested locations (SORS 36) demonstrated MD correlations with an R of 0.91 (p<0.0001). Reported R values for the correlation of MD values between DS and SORS remained very high even when the number of test locations was reduced to a third. Moreover, the correlation for tested and untested locations hardly differed, further demonstrating the strength of this novel visual field method.

Improved reliability

SORS also managed to perform optimally with regards to test-retest variability. Its test-retest variability was smaller than that of Dynamic Strategy: i.e. standard deviations and limits of agreement for SORS test-retest differences were smaller than those for DS. This suggests that SORS VFTs are reliable enough to decouple glaucoma progression from measurement variation. The variation between SORS and DS was also similar (even smaller) than DS test-retest variability, as illustrated by the standard deviation and limits of agreement lines. This points to non-inferiority of SORS compared to DS.

Built to scale, certified to deliver

VisionOne™ is more than a clinical breakthrough, it’s a solution ready for widespread adoption.

Certified with FDA, CE, and MHRA registrations, the system meets the highest international standards for medical safety and performance. Already in use across Europe, the US, and Latin America, VisionOne™ integrates seamlessly into a variety of clinical environments thanks to its cloud-based platform, compatibility with standard EMRs, and support for multilingual workflows.

With strong clinical validation, real-world usability, and a scalable design, VisionOne™ is ready to bring next-generation glaucoma diagnostics to practices around the world.

Designed for clinical workflow

The VisionOne™ platform includes a technician dashboard to schedule and configure tests and a clinician dashboard to analyze results. Both are intuitive, reducing training needs and saving time.

Conclusion: bringing diagnostics closer to people

For too long, visual field testing has been a barrier, logistically, emotionally, and clinically. VisionOne™ is changing that. With a device that’s faster, smarter, portable, and clinically trusted, we’re moving toward proactive eye care that puts people first.

As Patrick Kessel, CEO of PeriVision, says:

"At PeriVision, we’re redefining glaucoma diagnostics by merging breakthrough technology with a patient- and clinician-focused design philosophy. Our goal is to create tools that fit seamlessly into clinical practice. Ultimately, they should empower eye doctors to deliver better and more efficient care and help patients access this care to preserve their vision for longer."

Want to see VisionOne™ in action?

Book a demo or reach out to learn more about how VisionOne can help your practice deliver better eye care.

Contact us!